Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.
PLoS Biol. 2022 Feb 25;20(2):e3001547. doi: 10.1371/journal.pbio.3001547. eCollection 2022 Feb.
PLoS Biol. 2022.
PMID: 35213538
Free PMC article.